Cargando…

The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer

BACKGROUND: Immune checkpoint inhibitors play a vital role in triple-negative breast cancer (TNBC) immunotherapy. A recent study showed that chemokine-like factor (CKLF)-like MARVEL transmembrane domain containing 6 (CMTM6) has a crucial role in programmed death-ligand 1 (PD-L1) stability. The aim o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Yiping, Sun, Xiaohui, Cheng, Guoping, Ji, Enming, Yang, Shifeng, Feng, Jianguo, Zheng, Linfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867887/ https://www.ncbi.nlm.nih.gov/pubmed/33569433 http://dx.doi.org/10.21037/atm-20-7616

Ejemplares similares

Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer
por: Shi, Shuai, et al.
Publicado: (2022)

Analysis of CMTM6 and CMTM4 expression as potential regulators of the PD-L1 protein and its association with prognosis in glioma cancer
por: Xue, Hui, et al.
Publicado: (2022)

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
por: Mezzadra, Riccardo, et al.
Publicado: (2017)

Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers
por: Takeuchi, Hiroto, et al.
Publicado: (2020)

CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers
por: Gao, Feng, et al.
Publicado: (2019)

CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment
por: Zhang, Tong, et al.
Publicado: (2022)

CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients
por: Li, Xin, et al.
Publicado: (2020)

CMTM6 and CMTM7: New leads for PD‐L1 regulation in breast cancer cells undergoing EMT
por: Xiao, Malina, et al.
Publicado: (2022)

Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer
por: Zhang, Chao, et al.
Publicado: (2021)

Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer
por: Xiao, Malina, et al.
Publicado: (2021)

CMTM6 Stabilizes PD‐L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma
por: Yugawa, Kyohei, et al.
Publicado: (2020)

Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma
por: Liu, Li-Li, et al.
Publicado: (2020)

CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer
por: Peng, Qi-Hua, et al.
Publicado: (2021)

CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer
por: Wu, Xuehui, et al.
Publicado: (2021)

circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622/CMTM6 axis to promote triple-negative breast cancer and immune escape
por: Dong, Li-Feng, et al.
Publicado: (2023)

Co-Expression with Membrane CMTM6/4 on Tumor Epithelium Enhances the Prediction Value of PD-L1 on Anti-PD-1/L1 Therapeutic Efficacy in Gastric Adenocarcinoma
por: Wang, Ziqi, et al.
Publicado: (2021)

Expression and clinical significance of CMTM1 in hepatocellular carcinoma
por: Song, Xin, et al.
Publicado: (2021)

CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1
por: Zeisbrich, Markus, et al.
Publicado: (2021)

High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence
por: Muranushi, Ryo, et al.
Publicado: (2021)

Overexpressed CMTM6 Improves Prognosis and Associated With Immune Infiltrates of Ovarian Cancer
por: Yin, Bo, et al.
Publicado: (2022)

Cytomembranic PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma
por: Zheng, Linfeng, et al.
Publicado: (2017)

HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer
por: Liu, Yanbin, et al.
Publicado: (2021)

Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1–Independent Manner
por: Long, Yiru, et al.
Publicado: (2023)

The risk of PD-L1 expression misclassification in triple-negative breast cancer
por: Ben Dori, Shani, et al.
Publicado: (2022)

Clinical significance of CMTM4 expression in hepatocellular carcinoma
por: Bei, Chunhua, et al.
Publicado: (2017)

Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment
por: Zhao, Yanbin, et al.
Publicado: (2021)

CMTM6 expression as a potential biomarker for immunotherapy in metastatic renal cell carcinoma
por: Tulchiner, Gennadi, et al.
Publicado: (2021)

Expression of CMTM4 shows clinical significance in lung cancer
por: Zhu, Xiaonian, et al.
Publicado: (2020)

The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers
por: Barrett, Michael T., et al.
Publicado: (2018)

CMTM6 expressed on the adaxonal Schwann cell surface restricts axonal diameters in peripheral nerves
por: Eichel, Maria A., et al.
Publicado: (2020)

Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy
por: Martinez-Morilla, Sandra, et al.
Publicado: (2020)

CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas
por: Guan, Xiudong, et al.
Publicado: (2018)

MicroRNA-582-5p promotes triple-negative breast cancer invasion and metastasis by antagonizing CMTM8
por: Zeng, Xue, et al.
Publicado: (2021)

The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer
por: Mori, Hitomi, et al.
Publicado: (2017)

Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
por: Sun, Woo Young, et al.
Publicado: (2016)

CMTM6 is highly expressed in lung adenocarcinoma and can be used as a biomarker of a poor diagnosis
por: Jia, Daqi, et al.
Publicado: (2023)

PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis
por: Khan, Muhammad, et al.
Publicado: (2023)

PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker
por: Guo, Lei, et al.
Publicado: (2016)

Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2021)

Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell–Mediated Antitumor Immunity Through PD‐L1
por: Chui, Noreen Nog‐Qin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0qjgte5mfk9emsv5ofru3o4kvu